Update shared on 30 Oct 2025
Fair value Decreased 7.36%Narrative Update: NovoCure Analyst Price Target Adjusted
Analysts have modestly reduced their price target for NovoCure from $27.19 to $25.19. They cite increased long-term conservatism in their latest models.
Analyst Commentary
Recent activity in analyst coverage has reflected a mixture of optimism and caution regarding NovoCure's growth prospects and valuation. The following points summarize the key bullish and bearish perspectives underpinning the updated price targets.
Bullish Takeaways- Bullish analysts note that NovoCure maintains a solid foundation in its core technology, which may offer resilience even in a more conservative growth scenario.
- There is recognition that the company’s execution in ongoing clinical programs and partnerships remains steady, supporting its long-term positioning in the oncology space.
- Despite target adjustments, analysts believe the stock’s valuation already reflects heightened caution. This could provide upside if execution improves.
- Bearish analysts highlight that revised models incorporate lower growth expectations, reflecting concerns about the company’s ability to achieve aggressive long-term targets.
- Increased conservatism stems from ongoing uncertainty around reimbursement and commercial adoption for key products.
- The reduced price target underscores the risk that execution may fall short of prior high expectations, particularly given a competitive and regulatory environment.
What's in the News
- Final results from the Phase 3 METIS trial of Tumor Treating Fields (TTFields) therapy for brain metastases from non-small cell lung cancer (NSCLC) will be presented at the 2025 ASTRO Annual Meeting and published in the International Journal of Radiation Oncology Biology and Physics. (Key Developments)
- Japan's Ministry of Health has approved Optune Lua for concurrent use with PD-1/PD-L1 inhibitors to treat adult patients with unresectable advanced or recurrent NSCLC who have progressed after platinum-based chemotherapy. (Key Developments)
- Spain's Ministry of Health has made TTFields therapy available through the Spanish National Health System for adult patients with newly diagnosed glioblastoma. (Key Developments)
- NovoCure has submitted a premarket approval application to the FDA for TTFields therapy in locally advanced pancreatic cancer, supported by positive results from the PANOVA-3 trial. Approval is anticipated in the second half of 2026. (Key Developments)
Valuation Changes
- Consensus Analyst Price Target has decreased modestly, moving from $27.19 to $25.19.
- Discount Rate has decreased slightly, shifting from 8.21 percent to 8.07 percent.
- Revenue Growth forecast has edged up, increasing from 11.07 percent to 11.11 percent.
- Net Profit Margin has improved marginally, rising from 12.49 percent to 12.64 percent.
- Future P/E ratio has declined, moving from 39.29x to 35.78x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.